Full-Time
France Comm Cap lead
Updated on 8/12/2026
Johnson & Johnson
10,001+ employees
Global healthcare company offering pharma, devices.
Compensation Overview
€73.2k - €125.7k/yr
Paris, France
Hybrid
Hybrid work arrangement in Issy-les-Moulineaux; on-site days required as per local policy.
 Business & Strategy (1) |
|---|
Get referred to Johnson & Johnson
See people who can refer or advise you
- Manages other managers, supervisors, and/or individual contributors in a matrix environment, and is accountable for meaningful career development conversations and regular coaching and feedback.
- Communicates the direction of sales strategies throughout the sales lifecycle, from creating, maintaining and growing Pricing & Contracting/Tendering strategy, and coordinating the implementation of end-to-end Pricing and Contracting/Tender operational excellence designed to meet sales objectives.
- Contributes to business growth opportunities by improving Pricing & Contracting/Tendering processes and strategic opportunities, implementing continuous improvement & automation programs, generating performance metrics, and disseminating information that promotes a favorable view of the organization and its products and services.
- Maintains an extensive knowledge of DPS portfolio, process troubleshooting and benchmark industry best practices in order to assess customer needs and recommend appropriate strategies and solutions.
- Partner to country Leadership Team providing strategic decision making support, coaching Commercial Capability organization in bringing expertise to local General Manager and commercial leaders.
- Responsible for establishing country/cluster pricing strategy including Floor Price frameworks and compliance governance implemented via local operational execution excellence
- Delivers Price & Contracting/Tendering vision and strategy for the commercial organization by retaining and applying an in-depth understanding of customer needs and leveraging those insights to create an unparalleled sales experience.
- Participates in the design of strategic sales plans derived from corporate goals and customer touchpoints that leverage consumer data and customer insight to optimize Pricing & Contracting/Tendering enablement and ensure the achievement of sales objectives.
- Designs key performance indicators to measure the performance of Pricing & Contracting/Tendering departments and benchmark the organization’s capabilities with competitors and industry leading standards.
- Develops relationships with leaders and stakeholders to understand consumer priorities, identify capability gaps, conduct on-going needs assessments, and translate needs into targeted solutions.
- Responsible for managing operational aspects of their teams (e.g., budget, performance, and compliance), as well as implementing workforce and succession plans to meet business needs.
- Proactively creates a purpose driven environment by aligning Credo and Leadership Imperatives with the strategies and goals of the team and enterprise.
- Coaching
- Collaboration
- Customer Centricity
- Developing Others
- Efficiency Analysis
- Inclusive Leadership
- Leadership
- Marketing Integration
- Market Savvy
- Performance Measurement
- Process Optimization
- Sales Enablement
- Sales Support
- Solutions Selling
- Strategic Sales Planning
- Team Management
Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
New Brunswick, New Jersey
Founded
1886
Get referred to Johnson & Johnson
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales rose 6.6% to $25.3 billion, and guidance lifted to $101.1 billion.
- Tremfya grew 72.5% in Q2 2026, offsetting Stelara's patent loss.
- OTTAVA's July 2026 launch plus ongoing hernia trials create a long runway for adoption.
What critics are saying
- Stelara biosimilars and Medicare price cuts pressure immunology revenue throughout 2026.
- Talc settlement still needs 95% claimant approval, and future lawsuits remain outside coverage.
- Abiomed Impella weakness and surgeon skepticism threaten MedTech growth if Q3 volumes stay soft.
What makes Johnson & Johnson unique
- J&J spans pharmaceuticals, MedTech, and consumer health, reducing single-product dependence.
- OTTAVA gained FDA authorization on July 22, 2026, opening a new soft-tissue robotics category.
- AAA credit status and 64-year dividend streak signal exceptional capital discipline.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Remote Work Options
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -2%Johnson & Johnson leads a portfolio of four dividend-growth stocks that together generate $2,304 in annual passive income from a $100,000 investment split equally. The group delivers a 2.30% blended yield. SBA Communications tops the quartet with a 2.58% yield. Johnson & Johnson brings a 64-year dividend streak and AAA credit rating, making it a core income holding. Equinix, which converted to a REIT in 2015, runs the world's largest neutral interconnection footprint. The company generated $2.63 billion in Q2 revenue and has grown its quarterly payout from $2.66 in 2020 to $5.16 today. Institutions own 99.6% of the float. All four stocks trade on major exchanges with tight spreads, offering liquidity advantages over alternatives like rental real estate or mortgage REITs.
Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.
Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.
Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.
Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.